Accordingly, carriers of loss-of-function (LOF) mutations in apolipoprotein C3, a protein that inhibits LPL activity, have lower levels of plasma triglycerides and are less prone to coronary heart disease.3 Additionally, variants of the LPL gene coding for LOF are associated with increased risk of coronary heart disease.12 The gene discussed is LPL; the disease is coronary artery disorder.